Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.10.2 (
focal adhesion kinase
)
44,029
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The functional significance of decreased
RAP1GAP protein
expression in human tumors is unclear. To identify targets of RAP1GAP downregulation in the thyroid gland, RAP1 and RAP2 protein expression in human thyroid cells and in primary thyroid tumors were analyzed. RAP1GAP and RAP2 were co-expressed in normal thyroid follicular cells. Intriguingly, RAP1 was not detected in normal thyroid cells, although it was detected in papillary thyroid carcinomas, which also expressed RAP2. Both RAP proteins were detected at the membrane in papillary thyroid tumors, suggesting that they are activated when RAP1GAP is downregulated. To explore the functional significance of RAP1GAP depletion, RAP1GAP was transiently expressed at the lowest level that is sufficient to block endogenous RAP2 activity in papillary and anaplastic thyroid carcinoma cell lines. RAP1GAP impaired the ability of cells to spread and migrate on collagen. Although RAP1GAP had no effect on protein tyrosine phosphorylation in growing cells, RAP1GAP impaired phosphorylation of
focal adhesion kinase
and paxillin at sites phosphorylated by
SRC
in cells acutely plated on collagen.
SRC
activity was increased in suspended cells, where it was inhibited by RAP1GAP. Inhibition of
SRC
kinase activity impaired cell spreading and motility. These findings identify
SRC
as a target of RAP1GAP depletion and suggest that the downregulation of RAP1GAP in thyroid tumors enhances
SRC
-dependent signals that regulate cellular architecture and motility.
...
PMID:RAP1GAP inhibits cytoskeletal remodeling and motility in thyroid cancer cells. 2269 7